Efficacy and safety of fecal microbiota transplantation in children with refractory functional abdominal pain disorders: an open-label pilot trial with exploratory microbiome analyses
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Background Fecal microbiota transplantation (FMT) rebuilds the gut microbiota, yet its efficacy in pediatric refractory functional abdominal pain disorders (FAPDs) is insufficiently described. The purpose of this study is to identify gut microbiota dysbiosis in pediatric FAPDs and to examine the effectiveness, safety, and microbial biomarkers of FMT in these patients. Methods In a two-phase study, gut microbiota (16 S rRNA sequencing) were compared between 47 children with FAPDs and 39 healthy controls. Thereafter, a non-randomized, open-label prospective pilot trial (ClinicalTrials.gov: NCT05753774) allocated the 47 refractory patients, according to guardian and/or patient preference, to receive FMT plus conventional therapy ( n = 26) or conventional therapy only ( n = 21). The trial was terminated early because of slow recruitment (47 of 50 planned participants). The primary endpoint was the composite response rate at weeks 4 and 8. Results At baseline, patients had significant gut microbiota dysbiosis: 3.5-fold Proteobacteria enrichment (20.6% vs. 5.8%; P < 0.001), 4.1-fold Escherichia–Shigella expansion (12.7% vs. 3.1%; P < 0.001), and reduced α-diversity (Shannon index 4.7 ± 1.1 vs. 5.4 ± 1.1; P = 0.002). FMT plus conventional therapy was associated with a higher composite response rate at week 4 (69.2% vs. 14.3%; RR 4.85, 95% CI 1.65–14.24; Fisher’s exact P < 0.001) and week 8 (80.8% vs. 47.6%; RR 1.70, 95% CI 1.04–2.76; P = 0.029), with significantly better adjusted symptom scores in the FMT group at both time points. Post-FMT, Faecalibacterium and Blautia increased (+ 44.5% and + 99.1%), while Escherichia–Shigella declined (− 19.2%). Exploratory random forest models (seven genera for diagnosis; four genera characterizing the post-FMT, response-associated microbial signature) yielded internally validated AUCs of 0.896 (95% CI 0.821–0.952) and 0.890 (95% CI 0.699–1.000), respectively. FMT showed favorable short-term tolerability, with transient constipation in 50.0% of patients and no severe adverse events. Conclusions In this open-label pilot trial, FMT plus conventional therapy was associated with higher short-term response rates that were maintained through week 8 in children with refractory FAPDs. Exploratory microbial signatures further demonstrated potential for both diagnosis and characterization of the post-treatment, response-associated microbial state, and pending external validation. Trial registration: This study is registered at ClinicalTrials.gov on 11 February 2023 (registration number: NCT05753774), before the enrollment of the first participant. https://clinicaltrials.gov/study/NCT05753774
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Keywords: fecal microbiota transplantation, functional abdominal pain disorders, pediatric patients, gut dysbiosis, Proteobacteria, Escherichia-Shigella, Faecalibacterium, Blautia, microbial biomarkers, treatment response, safety, conventional therapy, alpha diversity, symptom scores, 16S rRNA gene sequencing, pilot trial, early termination
Open Access status: gold
Estimated APC paid: $3,190
OpenAlex ID: W7214281058
